Ondansetron and Hepatic encephalopathy - a phase IV clinical study of FDA data

Summary:

Hepatic encephalopathy is reported as a side effect among people who take Ondansetron (ondansetron), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Xifaxan, and have Hepatitis c.

The phase IV clinical study analyzes which people have Hepatic encephalopathy when taking Ondansetron. It is created by eHealthMe based on reports of 122,217 people who have side effects when taking Ondansetron from the FDA, and is updated regularly.

What is Ondansetron?

Ondansetron has active ingredients of ondansetron. It is often used in nausea. eHealthMe is studying from 122,738 Ondansetron users. Check the latest studies of Ondansetron.

What is Hepatic encephalopathy?

Hepatic encephalopathy (spectrum of neuropsychiatric abnormalities in patients with liver failure) is found to be associated with 914 drugs and 1,259 conditions by eHealthMe. Check the latest studies of Hepatic encephalopathy.

On Jul, 21, 2026

122,217 people reported to have side effects when taking Ondansetron.
Among them, 123 people (0.1%) have Hepatic encephalopathy.

Could Ondansetron cause Hepatic encephalopathy?

Among these 123 people:

How long have people been on Ondansetron when they have Hepatic encephalopathy? *

Click here to view more results

What is the gender of people who have Hepatic encephalopathy when taking Ondansetron? *

Click here to view

What is the age of people who have Hepatic encephalopathy when taking Ondansetron? *

Click here to view more results

* Approximation only. Some reports may have incomplete information.

Do you take Ondansetron and have Hepatic encephalopathy?

- Check whether Hepatic encephalopathy is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Ondansetron:

Ondansetron (122,738 reports)

Hepatic encephalopathy treatments and more:

Hepatic encephalopathy (15,814 reports)

How severe was Hepatic encephalopathy and when was it recovered:

Hepatic encephalopathy in Ondansetron

Expand to all the drugs that have ingredients of ondansetron:

Hepatic encephalopathy and drugs with ingredients of ondansetron (128 reports)

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Ondansetron:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hepatic encephalopathy:

Hepatic encephalopathy (914 drugs)

Browse all the conditions that are associated with Hepatic encephalopathy:

Hepatic encephalopathy (1,259 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on ondansetron (the active ingredients of Ondansetron) and Ondansetron (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.